Omeros surges 22% on clarity for BLA resubmission for narsoplimab

by


A graph made of neon tubes in a room

Jonathan Kitchen

  • Omeros (NASDAQ:OMER) is up ~22% in Friday trading after stating that based on recent feedback from the U.S. FDA, it is “not aware of any other impediment to resubmitting the narsoplimab” Biologics License Application.
  • Narsoplimab is the company’s candidate for


Leave a Comment